The results suggest that AZ and Daiichi Sankyo could be in line for ... Gilead is also testing its drug as a first-line therapy for NSCLC in combination with Keytruda in a trial sponsored by ...

AstraZeneca and Daiichi Sankyo have submitted a ... datopotamab deruxtecan as a monotherapy and in combination with other anticancer treatments in various settings. AstraZeneca and Daiichi Sankyo ...

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

The first patients have been dosed in three global, randomized phase 3 trials evaluating the efficacy and safety of datopotamab deruxtecan (Dato-DXd)- ...

in combination with standard cytarabine/anthracycline induction therapy and cytarabine consolidation therapy for these patients, and as maintenance monotherapy thereafter. Daiichi Sankyo says ...

AstraZeneca (AZN) and Daiichi Sankyo have submitted a new Biologics License Application ... including an EGFR-directed therapy. The companies have voluntarily withdrawn the BLA in the US for ...

Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...

As one of the leading Japanese pharmaceutical companies with headquarters in Europe, Daiichi Sankyo aims to revolutionize ... is shifting toward targeted therapy. This approach, already ...

Oncolytics Biotech is seeking accelerated approval for its lead cancer therapy, pelareorep ... of ADC therapies such as ...

(Reuters) -The U.S. Food and Drug Administration approved Astellas' therapy to treat a type of ... cancer include AstraZeneca ...

Q2 2025 Earnings Conference Call October 31, 2024 2:30 AM ET. Company Participants. Hiroyuki Okuzawa - Representative Director, Presi ...